Haemonetics (HAE) Shares Outstanding (Diluted Average) (2009 - 2026)

Haemonetics has reported Shares Outstanding (Diluted Average) for 18 years, with the latest figure at $47.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) fell 6.65% year-over-year to $47.4 million; the trailing twelve-month figure through Mar 2026 stood at $47.4 million (down 6.65% YoY), and the FY2026 full-year result was $47.4 million, down 6.65% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $47.4 million, down from $47.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $51.7 million in Q3 2022, with the low at $47.4 million in Q1 2026.
• Average Shares Outstanding (Diluted Average) over 5 years is $50.5 million, with a median of $51.3 million recorded in 2022.
• Year-over-year, Shares Outstanding (Diluted Average) grew 1.46% in 2022 and declined 6.98% in 2025.
• Tracing HAE's Shares Outstanding (Diluted Average) over 5 years: stood at $51.2 million in 2022, then increased by 0.34% to $51.4 million in 2023, then decreased by 1.47% to $50.6 million in 2024, then retreated by 5.87% to $47.7 million in 2025, then decreased by 0.66% to $47.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $47.4 million (Q1 2026), $47.7 million (Q4 2025), and $47.7 million (Q3 2025), per Business Quant data.

Peer Comparison